<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859844</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01016</org_study_id>
    <nct_id>NCT02859844</nct_id>
  </id_info>
  <brief_title>Transcutaneous Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Many patients with neurological diseases suffer from neurogenic lower urinary tract&#xD;
      dysfunction (NLUTD), which often severely impairs quality of life, due to urinary urgency&#xD;
      with or without incontinence and voiding dysfunction. In addition, the upper urinary tract&#xD;
      may be jeopardized because of high intravesical pressure caused by detrusor overactivity with&#xD;
      concurrent detrusor-sphincter-dyssynergia and/or low bladder compliance. The treatment of&#xD;
      NLUTD is a challenge since conventional conservative therapies often fail and more invasive&#xD;
      treatments such as intradetrusor onabotulinumtoxinA injections, bladder augmentation and&#xD;
      urinary diversion have to be considered. Neuromodulation therapies including tibial nerve&#xD;
      stimulation (TNS) may be alternative non-invasive treatment options. Indeed, TNS is an&#xD;
      effective and safe treatment for idiopathic overactive bladder proven in randomized&#xD;
      controlled trials (RCTs), but its value in neurological patients is unclear. In a recent&#xD;
      systematic review, the investigators found evidence that TNS might become a promising&#xD;
      treatment option for NLUTD, however, more reliable data from well-designed RCTs are urgently&#xD;
      needed to reach definitive conclusions. However, the investigators study will be the first&#xD;
      adequately sampled and powered, randomized, placebo-controlled, double-blind trial assessing&#xD;
      transcutaneous TNS (TTNS) for NLUTD. This trial will provide significant insights into the&#xD;
      efficacy of TTNS in patients suffering from NLUTD and in the case that this treatment is&#xD;
      really effective in the neurological population, the investigators findings would completely&#xD;
      revolutionize the management of NLUTD in daily clinical practice. Moreover, this&#xD;
      interdisciplinary trial will relevantly influence the neurological and urological approach in&#xD;
      the management of NLUTD promoting future collaborative projects improving patients' medical&#xD;
      care and underlying the pioneering role of Switzerland in the rapidly developing and&#xD;
      ambitious research field of neuro-urology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination after a few pilot participants due to further protocol development&#xD;
  </why_stopped>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of voids</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of leakages</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of used pads</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post void residual (mL)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Neurogenic Bladder Dysfunction</condition>
  <arm_group>
    <arm_group_label>TTNS ON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutaneous tibial nerve stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTNS OFF</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham/placebo stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Tibial Nerve Stimulation (TTNS)</intervention_name>
    <arm_group_label>TTNS OFF</arm_group_label>
    <arm_group_label>TTNS ON</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory LUTD due to a neurological disorder:&#xD;
&#xD;
          -  Urgency frequency syndrome and/or urgency incontinence refractory to antimuscarinics&#xD;
             (pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics)&#xD;
&#xD;
          -  Chronic urinary retention refractory to alpha-blocker (pharmacotherapy with an&#xD;
             alpha-blocker for at least 4 weeks)&#xD;
&#xD;
          -  Combination of urgency frequency syndrome and/or urgency incontinence and chronic&#xD;
             urinary retention refractory to antimuscarinics (pharmacotherapy for at least 4 weeks&#xD;
             with at least 2 antimuscarinics) and alpha-blocker (pharmacotherapy with an&#xD;
             alpha-blocker for at least 4 weeks)&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Botulinum A toxin injections in the detrusor and/or urethral sphincter in the last 6&#xD;
             months&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Individuals especially in need of protection (according to Research with Human&#xD;
             Subjects published by the Swiss Academy of Medical Sciences&#xD;
             www.samw.ch/en/News/News.html)&#xD;
&#xD;
          -  No informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>EOC-Ospedale regional Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinik Balgrist</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

